AIMS: To investigate determinants and temporal developments of treatment strategies, 5-year survival and heart transplantation rates between patients treated at secondary and tertiary hospitals. METHODS AND RESULTS: Baseline characteristics, treatment and follow-up data from 2,023 patients with chronic systolic heart failure due to ischaemic or dilated cardiomyopathy enrolled between 1995 and 2005 (996 patients treated at a secondary hospital vs. 1,027 patients treated at a tertiary hospital) were prospectively compared. Patients treated at the secondary hospital setting were twice as likely to have ischaemic cardiomyopathy compared to the tertiary hospital setting as the underlying cause of heart failure (59.7% vs. 33.0%, respectively) and were almost a decade older (mean age 65.2 vs. 56.7 years, respectively). The use of guideline-recommended therapy increased in both centres over time. In direct temporal comparison, both guideline-adherent pharmacological therapy and device therapy were implemented earlier at the tertiary hospital. Survival rates were significantly lower among patients treated at the secondary hospital (log-rank test P < 0.0001). The combined endpoint of all-cause mortality and heart transplantation, however, was not significantly different after adjustment for differences in baseline characteristics (P = 0.44). CONCLUSION: This study demonstrates the marked disparity between the patient cohorts with chronic systolic heart failure presenting at secondary and tertiary hospitals. Though patient characteristics-particularly age, aetiology of heart failure and the time of implementation of pharmacological and device treatment of heart failure-differed significantly, after adjustment for differences in baseline characteristics, no substantial difference in the combined endpoint of all-cause mortality and HTX was found during the 5-year follow-up period.
AIMS: To investigate determinants and temporal developments of treatment strategies, 5-year survival and heart transplantation rates between patients treated at secondary and tertiary hospitals. METHODS AND RESULTS: Baseline characteristics, treatment and follow-up data from 2,023 patients with chronic systolic heart failure due to ischaemic or dilated cardiomyopathy enrolled between 1995 and 2005 (996 patients treated at a secondary hospital vs. 1,027 patients treated at a tertiary hospital) were prospectively compared. Patients treated at the secondary hospital setting were twice as likely to have ischaemic cardiomyopathy compared to the tertiary hospital setting as the underlying cause of heart failure (59.7% vs. 33.0%, respectively) and were almost a decade older (mean age 65.2 vs. 56.7 years, respectively). The use of guideline-recommended therapy increased in both centres over time. In direct temporal comparison, both guideline-adherent pharmacological therapy and device therapy were implemented earlier at the tertiary hospital. Survival rates were significantly lower among patients treated at the secondary hospital (log-rank test P < 0.0001). The combined endpoint of all-cause mortality and heart transplantation, however, was not significantly different after adjustment for differences in baseline characteristics (P = 0.44). CONCLUSION: This study demonstrates the marked disparity between the patient cohorts with chronic systolic heart failure presenting at secondary and tertiary hospitals. Though patient characteristics-particularly age, aetiology of heart failure and the time of implementation of pharmacological and device treatment of heart failure-differed significantly, after adjustment for differences in baseline characteristics, no substantial difference in the combined endpoint of all-cause mortality and HTX was found during the 5-year follow-up period.
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2009-04-14 Impact factor: 24.094
Authors: Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews Journal: N Engl J Med Date: 2002-03-19 Impact factor: 91.245
Authors: Michel Komajda; Pablo Lapuerta; Nancy Hermans; José Ramon Gonzalez-Juanatey; Dirk J van Veldhuisen; Erland Erdmann; Luigi Tavazzi; Philip Poole-Wilson; Claude Le Pen Journal: Eur Heart J Date: 2005-04-12 Impact factor: 29.983
Authors: Nancy M Albert; Gregg C Fonarow; Clyde W Yancy; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mark McBride; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh Journal: Am Heart J Date: 2010-02 Impact factor: 4.749
Authors: Gregg C Fonarow; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mark L McBride; Patches Johnson Inge; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh; Clyde W Yancy Journal: Circulation Date: 2010-07-26 Impact factor: 29.690
Authors: John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur Heart J Date: 2008-09-17 Impact factor: 29.983
Authors: Gregg C Fonarow; Clyde W Yancy; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mandeep Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh Journal: Am Heart J Date: 2007-07 Impact factor: 4.749
Authors: J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason Journal: Eur Heart J Date: 2003-03 Impact factor: 29.983
Authors: Andreas Schuchert; Carmine Muto; Themistoklis Maounis; Robert Frank; Rita Omega Ella; Alexander Polauck; Luigi Padeletti Journal: Clin Res Cardiol Date: 2013-03-31 Impact factor: 5.460
Authors: Tímea Gombos; Zsolt Förhécz; Zoltán Pozsonyi; Gábor Széplaki; Jan Kunde; George Füst; Lívia Jánoskuti; István Karádi; Zoltán Prohászka Journal: Clin Res Cardiol Date: 2012-02-29 Impact factor: 5.460
Authors: Lutz Frankenstein; Henrik Hees; Tobias Taeger; Hanna Froehlich; Andreas Dösch; Rita Cebola; Christian Zugck; Hugo A Katus Journal: Clin Res Cardiol Date: 2013-06-26 Impact factor: 5.460
Authors: Jin Li; Jennifer Franke; Regina Pribe-Wolferts; Benjamin Meder; Philipp Ehlermann; Derliz Mereles; Florian Andre; Mohamed Assem Abdelrazek; Constanze Merten; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas Journal: Clin Res Cardiol Date: 2014-10-21 Impact factor: 5.460
Authors: Jennifer Franke; Andreas Lindmark; Matthias Hochadel; Christian Zugck; Eva Koerner; Jeannette Keppler; Philipp Ehlermann; Ralph Winkler; Ralf Zahn; Hugo A Katus; Jochen Senges; Lutz Frankenstein Journal: Clin Res Cardiol Date: 2014-11-06 Impact factor: 5.460
Authors: Ken Lee Chin; Marina Skiba; Andrew Tonkin; Christopher M Reid; Danny Liew; Henry Krum; Ingrid Hopper Journal: Heart Fail Rev Date: 2016-11 Impact factor: 4.214
Authors: Marion Schowalter; Götz Gelbrich; Stefan Störk; Jan-Philip Langguth; Caroline Morbach; Georg Ertl; Hermann Faller; Christiane E Angermann Journal: Clin Res Cardiol Date: 2012-12-21 Impact factor: 5.460